PRA1B6 Antibody

What is PRAME and why is it significant in cancer research?

PRAME (Preferentially expressed antigen of melanoma) is a cancer-testis protein that functions as a transcriptional repressor. It inhibits retinoic acid signaling through the retinoic acid receptors RARA, RARB, and RARG, thereby preventing retinoic acid-induced cell proliferation arrest, differentiation, and apoptosis . PRAME is overexpressed in various cancers, making it valuable as both a diagnostic and prognostic marker for anticancer therapy. The protein is located in both the nucleus and cell membrane, offering multiple targeting opportunities for immunotherapeutic approaches .

What applications are PRAME antibodies used for in research?

PRAME antibodies have multiple research applications across various immunological techniques. They are commonly employed in ELISA (enzyme-linked immunosorbent assay) for quantitative detection, flow cytometry (FCM) for cell sorting and analysis, and various immunohistochemistry approaches including IHC-P (paraffin sections), IHC-F (frozen sections), and immunofluorescence techniques . Additionally, PRAME antibodies are utilized in immunocytochemistry (ICC) to determine protein localization at the cellular level. These diverse applications make PRAME antibodies versatile tools for cancer research, particularly in oncohematological diseases and melanoma studies .

What is the difference between polyclonal and monoclonal PRAME antibodies?

The key difference lies in their production and specificity characteristics:

Polyclonal antibodies like bs-7004R are derived from synthetic peptides of human PRAME (typically covering regions like 151-250/509) . In contrast, monoclonal antibodies such as 6H8 recognize a single epitope, making them valuable for specific detection of surface PRAME in applications like flow cytometry and confocal microscopy .

How can researchers optimize fluorescent labeling of PRAME antibodies?

Optimizing fluorescent labeling of PRAME antibodies requires careful consideration of both the labeling chemistry and the fluorophore selection. For direct labeling, protected-oxyamine derivatives of fluorescein-type dyes (FAM, Alexa488, BDP-FL) have proven effective, particularly for the 6H8 monoclonal antibody to PRAME . The labeling process typically involves periodate oxidation to generate aldehyde groups on the glycoside moieties of the immunoglobulin, followed by conjugation with oxyamine dyes. This approach preserves the antigen-binding domains, ensuring that the antibody retains its specificity and affinity .

Researchers should characterize the stoichiometry of the resulting conjugates spectroscopically to ensure optimal dye-to-antibody ratios. For applications requiring higher sensitivity, such as detection of PRAME in bone marrow samples from patients with oncohematological diseases, BDP-FL dye-labeled antibodies have demonstrated particularly high efficiency in flow cytometry quantification . The selection of fluorophore should be tailored to the specific experimental setup, including consideration of potential spectral overlap with other fluorophores in multiplexed assays.

What methodological approaches should be used when studying PRAME expression on the surface of cancer cells?

When investigating PRAME expression on cancer cell surfaces, researchers should implement a multi-modal approach combining flow cytometry and confocal microscopy for comprehensive characterization. For flow cytometric analysis, fluorescently labeled PRAME antibodies (such as 6H8) should be used with appropriate controls to quantify expression levels across different cell populations .

For confocal microscopy, a protocol involving live cell labeling prior to fixation is recommended to specifically detect the surface form of PRAME protein without interference from intracellular forms. This approach has been successfully demonstrated with K562 leukemic cells and melanoma cells . The protocol should include:

• Staining live cells with fluorescently-labeled anti-PRAME antibody (e.g., AF488-labeled 6H8)

• Fixation with paraformaldehyde to prevent permeabilization

• Counter-staining membrane structures with PKH26 and nuclei with DAPI

• Analysis by confocal microscopy to confirm surface localization

This methodology prevents binding to intracellular PRAME, allowing specific analysis of the surface-expressed protein which has implications for immunotherapy targeting .

How do different dilutions affect PRAME antibody performance across applications?

The optimal dilution of PRAME antibodies varies significantly depending on the application, significantly impacting sensitivity and specificity of detection. Based on empirical data for the bs-7004R polyclonal antibody:

Researchers should perform titration experiments to determine the optimal dilution for their specific experimental conditions, cell types, and detection systems . For critical applications, especially in clinical diagnostics, validation using positive and negative controls is essential to establish reliable detection thresholds.

What is the significance of PRA testing in transplantation research?

Panel-Reactive Antibody (PRA) testing serves as a critical screening measure to assess a potential organ recipient's degree of sensitization resulting from prior exposure to external HLA antigens through blood transfusions, pregnancies, or previous organ transplantations . The PRA titer, measured in all kidney transplant candidates on active waiting lists, is reported as both peak (maximum historical) and last pre-transplant values. These measurements inform the selection of appropriate immunosuppression protocols, including the type of induction therapy .

The significance of PRA testing is demonstrated by research showing that patients with elevated PRA titers (>20%) experience significantly higher rates of positive cross-matches and acute rejection episodes compared to non-sensitized patients. This finding is particularly important for transplantation research as it helps stratify patients according to immunological risk and guides clinical decision-making regarding immunosuppressive regimens .

How does the complement-dependent cytotoxicity test (PRA-CDC) methodology compare with newer detection methods?

The complement-dependent cytotoxicity test (PRA-CDC) remains a standard method for monitoring immunization in kidney transplant candidates in several countries despite advances in detection technology . When comparing methodologies:

What are the methodological approaches to studying the relationship between historical and current PRA titers?

When investigating the relationship between historical and current PRA titers, researchers should implement a retrospective cohort analysis with clear stratification criteria. Based on established research methodology, patients should be categorized into distinct groups based on both peak and last pre-transplant PRA titers:

• Non-sensitized group (non-ST): Patients with peak PRA <20%

• Currently sensitized group (ST): Patients with both peak and last pre-transplant PRA >20%

• Previously sensitized group (prev-ST): Patients with peak PRA >20% but current PRA ≤20%

Research endpoints should include measurable clinical outcomes such as:

• Percentage of positive crossmatches

• Incidence of primary graft non-function (PGN)

• Frequency of delayed graft function (DGF)

• Rate and type of acute rejection episodes (cellular, vascular, mixed, or antibody-mediated)

Statistical analysis should incorporate multiple logistic regression to adjust for potential confounding variables. Research has demonstrated that previously sensitized kidney transplant candidates, even with substantial decreases in pre-transplant PRA-CDC levels, remain at high immunological risk comparable to currently sensitized patients. This finding has significant implications for immunosuppression protocols, suggesting that historical sensitization should influence the selection of induction therapy regardless of current PRA levels .

What storage conditions maximize PRAME antibody stability and longevity?

Optimal storage of PRAME antibodies requires careful attention to temperature, buffer composition, and handling procedures. For the bs-7004R polyclonal antibody, the recommended storage buffer consists of 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300, and 50% Glycerol . This formulation provides protein stability, antimicrobial protection, and cryoprotection, respectively.

The shipping condition is typically 4°C, but for long-term storage, -20°C is recommended with an expected shelf life of one year when properly stored . Researchers should strictly avoid repeated freeze/thaw cycles as these can lead to antibody denaturation, aggregation, and loss of binding activity. For working solutions, aliquoting into single-use volumes is strongly advised to minimize freeze/thaw cycles. When transitioning from storage to experimental use, antibodies should be thawed gradually at reduced temperatures (e.g., on ice) rather than at room temperature to preserve functional integrity.

How should researchers interpret and troubleshoot variable PRAME expression in different cell types?

When encountering variable PRAME expression across different cell types or patient samples, researchers should implement a systematic approach to interpretation and troubleshooting:

• Biological variability assessment: PRAME expression varies naturally between cell types. For example, research has shown comparable PRAME protein levels on the surface of K562 leukemic cells and metastatic melanoma cells (mel P), while expression patterns differ in other cancer types .

• Antibody validation strategy: Researchers should validate antibody specificity using:

  • Positive controls (known PRAME-expressing cell lines like K562)

  • Negative controls (PRAME-negative cell lines or isotype controls)

  • Blocking experiments with recombinant PRAME protein

  • Parallel analysis with multiple anti-PRAME antibodies targeting different epitopes

• Technical considerations: Variable results may stem from:

  • Sample preparation differences (fixation methods, permeabilization)

  • Antibody concentration (titration may be required for each cell type)

  • Detection method sensitivity (flow cytometry vs. microscopy vs. Western blot)

  • Subcellular localization (surface vs. intracellular PRAME require different protocols)

• Quantification approach: For reliable comparison across samples, researchers should:

  • Use standardized quantification methods (MFI for flow cytometry)

  • Include calibration standards

  • Normalize to housekeeping proteins where appropriate

  • Report both percentage of positive cells and expression intensity

Understanding that PRAME exhibits dual localization (nucleus and cell membrane) is critical when interpreting experimental results and may explain apparent discrepancies between detection methods that preferentially detect one form over the other .

What controls are essential when studying PRAME antibodies in oncohematological diseases?

When utilizing PRAME antibodies to study oncohematological diseases, a comprehensive control strategy is essential for reliable and reproducible results:

• Cellular controls:

  • Positive control: K562 leukemic cell line (confirmed to express surface PRAME)

  • Negative control: PRAME-negative cell lines appropriate to the disease being studied

  • Patient-derived samples: Both disease and non-disease samples from the same patient when available

• Antibody controls:

  • Isotype control: Matched immunoglobulin at equivalent concentration

  • Blocking control: Pre-incubation with recombinant PRAME protein

  • Secondary antibody-only control: For indirect detection methods

  • Multiple anti-PRAME antibodies: Target different epitopes to confirm specificity

• Technical controls:

  • Unstained cells: For autofluorescence assessment

  • Single-color controls: For compensation in multicolor flow cytometry

  • Dilution series: To establish detection limits and optimal antibody concentration

  • Fixation controls: To assess the impact of fixation on epitope recognition

• Analytical controls:

  • Inter-assay calibrators: To allow comparison between experiments

  • Standardized gating strategy: For consistent flow cytometry analysis

  • Blinded analysis: To minimize observer bias

Research has demonstrated that these controls are particularly important when analyzing bone marrow samples from patients with oncohematological diseases, where PRAME expression may be heterogeneous and affected by treatment status . The implementation of rigorous control strategies ensures that observed PRAME expression patterns reflect biological reality rather than technical artifacts.

How might PRAME antibodies be utilized in developing immunotherapeutic approaches?

PRAME antibodies hold significant potential for immunotherapeutic development based on several key characteristics of the protein. PRAME's preferential expression in tumor cells with limited expression in normal tissues (except testis) makes it an ideal target for cancer-specific therapies . Future research directions should explore:

• Antibody-drug conjugates (ADCs): Coupling anti-PRAME antibodies with cytotoxic payloads to deliver targeted therapy to PRAME-expressing tumor cells. This approach would leverage the surface expression of PRAME on melanoma and leukemic cells demonstrated through flow cytometry and confocal microscopy .

• Bispecific antibodies: Developing bispecific constructs that simultaneously bind PRAME on tumor cells and CD3 on T cells to redirect cytotoxic T cells toward cancer cells.

• CAR-T cell therapy: Engineering T cells with chimeric antigen receptors incorporating anti-PRAME binding domains, potentially utilizing the same epitopes recognized by existing monoclonal antibodies like 6H8 .

• Therapeutic vaccines: Designing vaccines that elicit anti-PRAME immune responses, potentially enhanced by understanding the epitopes recognized by well-characterized antibodies.

• Combination approaches: Investigating synergistic effects of anti-PRAME therapies with agents that modulate retinoic acid signaling, given PRAME's role as a transcriptional repressor that inhibits retinoic acid signaling and prevents cell differentiation .

Research must address potential escape mechanisms, including heterogeneous PRAME expression within tumors and possible antigen downregulation in response to therapeutic pressure.

What methodological advancements might improve the sensitivity and specificity of PRA testing in transplantation research?

Advancing PRA testing methodologies remains crucial for improving transplantation outcomes. Future research should focus on:

• Integration of PRA-CDC and single antigen bead (SAB) testing: Developing cost-effective protocols that combine the accessibility of PRA-CDC with the precision of SAB testing, particularly for resource-limited settings .

• Standardized risk stratification algorithms: Creating validated algorithms that incorporate both historical and current PRA titers alongside SAB results to better predict immunological risk and guide immunosuppressive protocols .

• Machine learning approaches: Applying artificial intelligence to analyze complex patterns in historical sensitization data, crossmatch results, and clinical outcomes to identify previously unrecognized risk factors and improve prediction models.

• Point-of-care testing: Developing rapid, reliable PRA testing methods that can be performed at the time of organ allocation to minimize cold ischemia time while maintaining accuracy.

• Functional antibody assays: Moving beyond mere antibody detection to assess the functional capacity of detected antibodies to activate complement or stimulate endothelial cells, providing more clinically relevant risk assessment.

Research has demonstrated that despite substantial decreases in pre-transplant PRA-CDC levels, previously sensitized kidney transplant candidates remain at high immunological risk . These methodological advancements would help refine risk assessment and personalize immunosuppressive strategies.